The present invention provides a hydrogel manufacturing apparatus capable of suppressing contamination of impurities from formation of a hydrogel until usage thereof. A hydrogel manufacturing apparatus (100) comprises: a first flow path (212) through which a hydrogel precursor flows; a second flow path (222) through which a gelling agent for gelling the hydrogel precursor flows; a first merging point (216) between the first flow path (212) and the second flow path (222); a housing container (400) for housing a hydrogel formed by contact between the hydrogel precursor and the gelling agent; and a hydrogel flow path (300) for connecting at least the housing container (400) and the first merging point (216) in a closed manner.
B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
C12M 1/00 - Apparatus for enzymology or microbiology
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
D01F 9/04 - Man-made filaments or the like of other substancesManufacture thereofApparatus specially adapted for the manufacture of carbon filaments of alginates
2.
METHOD FOR PRODUCING CELL CAPSULE, METHOD FOR PRODUCING CELL POPULATION OR CELL PRODUCT, SOLUTION, AND CELL POPULATION
Provided is a method for producing a cell capsule capable of alleviating an adverse effect on a cell. This method for producing a cell capsule includes continuously or intermittently causing a hydrogel or a hydrogel precursor covering a cell to flow into a collection solution. The collection solution contains a pH buffer.
A cell population comprises a large number of cell aggregations and a hydrogel encapsulating the large number of cell aggregations. A coefficient of variation obtained by dividing a standard deviation of sizes of the large number of cell aggregations by a mean value of the sizes of the large number of cell masses is 0.50 or less. Alternatively and/or in addition there to, a coefficient of variation obtained by dividing a standard deviation of aspect ratios of shapes of the large number of cell aggregations by a mean value of the aspect ratios of the shapes of the large number of cell aggregations is 0.30 or less.
The present invention provides a method for producing a cell population capable of providing an improved method for causing a cell to take up a substance to be introduced. This method for producing a cell population comprises covering a substance to be delivered and a cell by a semipermeable membrane (14) and forming a cell capsule (10), and culturing the cell in the cell capsule (10).
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
5.
CELL CAPSULE, CELL POPULATION, AND METHOD FOR PRODUCING CELL POPULATION
Provided is a method for producing a novel cell population containing CD56-positive immune cells. The method for producing a cell population includes: forming a cell capsule (10) by covering a core (12), in which CD56-positive immune cells or precursor cells of CD56-positive immune cells are suspended, with a semipermeable membrane (14); and culturing the cell capsule (10) by immersing the cell capsule (10) in a medium.
Provided is a structure with which a lung progenitor cells can proliferate while retaining an ability to differentiate into an alveolar epithelial cell and an airway epithelial cell. A structure of the present invention includes a core portion that includes a cell population, and an outer shell portion that covers at least a part of the core portion and contains a hydrogel. The structure has a storage elastic modulus of 150 Pa or more and/or the hydrogel contains alginic acid. The cell population contains an alveolar epithelial cell, an airway epithelial cell, and/or a progenitor cell thereof.
Provided is a method for producing cells or cell aggregates and/or cell products, the method facilitating removal of hydrogel-derived substances. The present invention provides a method for producing cells or cell aggregates and/or cell products, the method including: employing a capsule containing a core base material and a shell that covers the core base material to culture cells or cell aggregates in the core base material, thus obtaining cells or cell aggregates and/or cell products; and physically destroying or cutting at least the shell to obtain the cells or the cell aggregates and/or the cell products.
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
C12M 1/00 - Apparatus for enzymology or microbiology
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
The purpose of the present invention is to provide an exosome production method which makes it possible to produce an exosome with high efficiency. The exosome production method comprises: a step for culturing a cell (12) using a cell fiber (10) comprising a hydrogel (14) having a hollow fiber-like form and the cell (12) encapsulated in the inner cavity of the hydrogel; and a step for collecting an exosome released from the cell (12).
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12M 1/00 - Apparatus for enzymology or microbiology
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (Japan)
Inventor
Inamori, Masakazu
Hino, Motohiro
Amimoto, Naoki
Tatsumi, Rie
Ikeda, Kazuhiro
Taniguchi, Hideki
Okamoto, Satoshi
Abstract
The present invention provides a method for mass producing cell aggregates such as artificial organoids through an approach that differs entirely from previous methods. Specifically, provided is a method for producing cell aggregates that includes a step in which a mixture of mesenchymal stem cells, vascular endothelial cells, and organ cells are filled into microfibers, and the mixture is suspension cultured to form cell aggregates.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
Provided is a novel structure containing mesenchymal stem cells that can be used in various applications. A hydrogel fiber (10) comprises a hydrogel (14) that contains mesenchymal stem cells.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
11.
SCAFFOLD, METHOD FOR PRODUCING SCAFFOLD, CELL CULTURE CONSTRUCT, METHOD FOR CULTURING CELL
A scaffold for culturing a cell comprises: a hydrogel; and a plasma-derived or platelet-derived component or a fibrin-containing material adhered to the hydrogel.
This cell population includes a large number of cell clusters and a hydrogel that covers the large number of cell clusters. A coefficient of variation obtained by dividing the standard deviation of the size of the cell clusters by the average value of the size of the cell clusters is not more than 0.50. Alternatively, or in addition thereto, a coefficient of variation obtained by dividing the standard deviation of the aspect ratios of the shapes of the cell clusters by the average value of the aspect ratios of the shapes of the cell clusters is not more than 0.30.
Provided is a structure for enabling proliferation of lung progenitor cells while maintaining the ability of the lung progenitor cells to differentiate into alveolar epithelial cells and airway epithelial cells. This structure is provided with a core part that encapsulates a cell population and an outer shell part that at least partially covers the core part and that contains a hydrogel, the structure having a storage elastic modulus of 150 Pa or above and/or alginic acid being contained in the hydrogel, and the cell population including alveolar epithelial cells, airway epithelial cells, and/or progenitor cells thereof.
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
14.
CELL FIBER, CELL FIBER PRODUCTION SYSTEM, CELL FIBER PRODUCTION METHOD, AND PROGRAM
A cell fiber production system comprises: a first flow path through which a first fluid containing a cell flows; a second flow path for allowing a second fluid for preparing a hydrogel to converge around the first fluid in the first flow path; and an ejection port through which at least the first fluid and the second fluid are discharged together. The cell fiber production system is constructed that, at a start stage of production of a cell fiber, the first fluid is delivered after the second fluid reaches at least a convergence point between the first flow path and the second flow path.
Provided is a novel structure containing mesenchymal stem cells that can be used in various applications. A hydrogel fiber (10) comprises a hydrogel (14) that contains mesenchymal stem cells.
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
16.
SCAFFOLD, METHOD FOR PRODUCING SCAFFOLD, CELL CULTURE, CELL CULTURE METHOD
A scaffold (10) for culturing cells has a hydrogel (12) and a plasma-derived or platelet-derived component or a fibrin-containing substance (14) attached to the hydrogel (12).
A storage body (10) has a storage modulus (G') of 100 Pa or more at a frequency of 1 Hz, and includes a hydrogel (14) having cells or cell aggregates (12) enclosed therein. The hydrogel (14) has a cylindrical shape extending continuously.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemicals used in industry; Protein in raw material form for scientific and medical research; Enzymes for scientific and research purposes; Bacteriological preparations, other than for medical and veterinary use; Bacteriological preparations for acetification other than for medical or veterinary use; Biological preparations, other than for medical or veterinary purposes; Biological tissue cultures, other than for medical or veterinary purposes; Chemical preparations for scientific purposes, other than for medical or veterinary use; Cultures of microorganisms, other than for medical and veterinary use; Milk ferments for chemical purposes for industrial purposes; Preparations of microorganisms, other than for medical and veterinary use; Stem cells, other than for medical or veterinary purposes; none of the foregoing for use in agriculture, horticulture or forestry Dietary supplements; Dietetic beverages adapted for medical purposes; Dietetic food adapted for medical purposes; Food for babies; Dietary supplements for animals, other than drugs; Pharmaceutical preparations for the treatment of diseases and disorders of the metabolic system, cardiovascular system, respiratory system, nervous system, skin system, digestive system, endocrine system, urinary system, blood system, reproductive system, namely, pharmaceutical preparations for the treatment of cancers, autoimmune diseases, and neurological disorders; Medicines for veterinary purposes for the treatment of diseases and disorders of the metabolic system, cardiovascular system, respiratory system, nervous system, skin system, digestive system, endocrine system, urinary system, blood system, reproductive system, namely, pharmaceutical preparations for the treatment of cancers, autoimmune diseases, and neurological disorders; Biological preparations for the treatment of diseases and disorders of the metabolic system, cardiovascular system, respiratory system, nervous system, skin system, digestive system, endocrine system, urinary system, blood system, reproductive system, namely, pharmaceutical preparations for the treatment of cancers, autoimmune diseases, and neurological disorders; Biological preparations for the treatment of cancers, autoimmune diseases, and neurological disorders for veterinary purposes; Reagent paper for medical purposes Providing computer programs on data networks, namely, providing temporary use of online non-downloadable software for use in operation control of laboratory apparatus and instruments; Rental of laboratory apparatus and instruments; Bacteriological research; Biological research; Chemical analysis; Chemical research; Chemistry services, namely, chemistry consultation, research in the field of chemistry, laboratory research and analysis in the field of chemistry; Research and development of new products for others; Scientific laboratory services; Scientific research; Designing of machines, apparatus, instruments, including their parts, or systems composed of such machines, apparatus and instruments; Computer programming; Technological advice relating to the operation of computers; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; Testing, inspection or research on cell systems in the fields of agriculture, livestock breeding or fisheries; Testing the functionality of machines, apparatus and instruments; research on machines, apparatus and instruments; Rental of measuring apparatus; Rental of computers
An additional method for producing an antibody was needed. Provided are: a chemically crosslinked alginate gel fiber which is for producing an antibody and in which an antibody-producing cell (for example, an antibody-producing CHO cell) is contained in a core layer; and a method for producing an antibody using said alginate gel fiber.
This cellular fiber production system has a first flow path through which a first fluid containing cells flows, a second flow path which causes a second fluid for preparation of a hydrogel to merge around the first fluid in the first flow path, and an outlet opening through which at least the first and second fluids are discharged together. This cellular fiber production system is configured so that during the start of production of cellular fibers, the first fluid is fed at least after the second fluid reaches a point where the first and second flow paths merge together.
